The complexity of the tumor microenvironment is highlighted by single‐cell sequencing studies showing high ANXA1 expression across all immune cells in the context of PD‐1/PD‐L1 drug resistance, suggesting an adaptive response of the tumor microenvironment to ICB treatments. This evidence concerns the gene RPL17 and neoplasm.